Similar articles for PMID: 29602822

Year	Number of Results
1991	1
1992	1
1993	1
1995	1
1996	2
1997	4
1999	4
2000	1
2001	2
2002	1
2003	1
2004	6
2006	1
2007	2
2008	6
2009	3
2010	3
2011	5
2012	5
2013	9
2014	4
2015	12
2016	20
2017	16
2018	13
2019	11
2020	25
2021	22
2022	17
2023	9
2024	0

1

¹⁸F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.

Nienhuis HH, van Kruchten M, Elias SG, Glaudemans AWJM, de Vries EFJ, Bongaerts AHH, Schröder CP, de Vries EGE, Hospers GAP. Nienhuis HH, et al. J Nucl Med. 2018 Aug;59(8):1212-1218. doi: 10.2967/jnumed.117.198846. Epub 2018 Mar 30. J Nucl Med. 2018. PMID: 29602822 Free article.

2

Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?

Yang Z, Sun Y, Zhang Y, Xue J, Wang M, Shi W, Zhu B, Hu S, Yao Z, Pan H, Zhang Y. Yang Z, et al. Clin Breast Cancer. 2013 Oct;13(5):359-63. doi: 10.1016/j.clbc.2013.02.012. Epub 2013 Jun 17. Clin Breast Cancer. 2013. PMID: 23787040

3

The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.

Yang Z, Sun Y, Xu X, Zhang Y, Zhang J, Xue J, Wang M, Yuan H, Hu S, Shi W, Zhu B, Zhang Y. Yang Z, et al. Clin Nucl Med. 2017 Jun;42(6):421-427. doi: 10.1097/RLU.0000000000001587. Clin Nucl Med. 2017. PMID: 28221191

4

Head-to-Head Evaluation of ¹⁸F-FES and ¹⁸F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer.

Ulaner GA, Jhaveri K, Chandarlapaty S, Hatzoglou V, Riedl CC, Lewis JS, Mauguen A. Ulaner GA, et al. J Nucl Med. 2021 Mar;62(3):326-331. doi: 10.2967/jnumed.120.247882. Epub 2020 Jul 17. J Nucl Med. 2021. PMID: 32680923 Free PMC article.

5

Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.

Venema CM, Mammatas LH, Schröder CP, van Kruchten M, Apollonio G, Glaudemans AWJM, Bongaerts AHH, Hoekstra OS, Verheul HMW, Boven E, van der Vegt B, de Vries EFJ, de Vries EGE, Boellaard R, Menke van der Houven van Oordt CW, Hospers GAP. Venema CM, et al. J Nucl Med. 2017 Dec;58(12):1906-1912. doi: 10.2967/jnumed.117.193649. Epub 2017 Sep 14. J Nucl Med. 2017. PMID: 28912144 Free article. Clinical Trial.

6

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using ¹⁸F-FES PET/CT imaging.

Jager A, de Vries EGE, der Houven van Oordt CWM, Neven P, Venema CM, Glaudemans AWJM, Wang Y, Bagley RG, Conlan MG, Aftimos P. Jager A, et al. Breast Cancer Res. 2020 Sep 11;22(1):97. doi: 10.1186/s13058-020-01333-3. Breast Cancer Res. 2020. PMID: 32912274 Free PMC article. Clinical Trial.

7

Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer ¹⁸F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial.

Paquette M, Lavallée É, Phoenix S, Ouellet R, Senta H, van Lier JE, Guérin B, Lecomte R, Turcotte ÉE. Paquette M, et al. J Nucl Med. 2018 Feb;59(2):197-203. doi: 10.2967/jnumed.117.194654. Epub 2017 Aug 10. J Nucl Med. 2018. PMID: 28798032 Free PMC article. Clinical Trial.

8

Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.

Gemignani ML, Patil S, Seshan VE, Sampson M, Humm JL, Lewis JS, Brogi E, Larson SM, Morrow M, Pandit-Taskar N. Gemignani ML, et al. J Nucl Med. 2013 Oct;54(10):1697-702. doi: 10.2967/jnumed.112.113373. Epub 2013 Aug 22. J Nucl Med. 2013. PMID: 23970364 Free PMC article. Clinical Trial.

9

Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.

Boers J, Venema CM, de Vries EFJ, Glaudemans AWJM, Kwee TC, Schuuring E, Martens JWM, Elias SG, Hospers GAP, Schröder CP. Boers J, et al. Eur J Cancer. 2020 Feb;126:11-20. doi: 10.1016/j.ejca.2019.10.024. Epub 2019 Dec 28. Eur J Cancer. 2020. PMID: 31891878 Clinical Trial.

10

A Randomized Feasibility Study of ¹⁸F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer.

Chae SY, Kim SB, Ahn SH, Kim HO, Yoon DH, Ahn JH, Jung KH, Han S, Oh SJ, Lee SJ, Kim HJ, Son BH, Gong G, Lee HS, Moon DH. Chae SY, et al. J Nucl Med. 2017 Apr;58(4):563-568. doi: 10.2967/jnumed.116.178368. Epub 2016 Sep 29. J Nucl Med. 2017. PMID: 27688475 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

176 results

Results by year